Juliya Fortuna Hand, PA
Physician Assistant · Lancaster
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 12
- Since medical school
- 9 years
- Graduated 2017
Offices
12 locations · Lancaster General Medical Group · 590 clinicians in this group
Looking this up.
Hospitals listed: Lancaster General Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Juliya Fortuna Hand’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lancaster General HospitalLancaster, PAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of Pennsylvania Health System, which runs 9 hospitals in 2 statesPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.468, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.287, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.302, Oct 2024 – Sep 2025
See every measure and the patient survey for Lancaster General Hospital
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 4 better, 7 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.468 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.287 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.302 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0.1 to 1.73) · 2,404 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.65 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 187.26 (147.92 to 226.61) · 145 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.4 · 266 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 414 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 1,089 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.9 · 760 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.8 · 1,000 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 7,981 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.31) · 14,183 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.07 to 0.4) · 14,301 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.38 (2.84 to 5.92) · 3,900 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.03 (0 to 2.22) · 1,624 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.3 (1.08 to 3.51) · 3,338 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7 (2.89 to 11.1) · 1,623 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.37 (0.57 to 6.17) · 1,575 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.26 to 2.91) · 855 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.67 (0.21 to 1.12) · 12,569 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 223 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.446 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.535 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.82 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 677 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.2 · 1,739 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 2.4 · 426 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.9 · 1,195 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -11 · 785 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 14.9 · 1,106 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (4.7 to 7.7) · 578 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.9 (9.8 to 14.4) · 578 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 211 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 227 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18 · 526 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.2 to 15.3) · 1,174 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 1,604 cases | No different | Jan 2024 – Dec 2024 |
What patients said (462 patients answered, 28% of those asked)
| Cleanliness | 2 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 90% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 37% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$39,834
Medicare paid this office $39,834 for 313 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 182 | $18,996 | $76 |
| New patient visit (45+ min) | 103 | $9,923 | $96 |
| Short return visit (20+ min) | 71 | $4,175 | $55 |
| New patient visit (60+ min) | 26 | $3,401 | $131 |
| Long return visit (40+ min) | 26 | $3,138 | $108 |
Who their Medicare patients are
313 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 10% · Women 51% · Also on Medicaid 8% · Health risk score 1.37. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Coronary heart disease 35% · Diabetes 32% · Chronic kidney disease 32% · Depression 31% · COPD 27% · Atrial fibrillation 24% · Heart failure 23% · Cancer 19% · Stroke 10% · Dementia 9%.
The office billed $135,829, Medicare allowed $54,013 and paid $39,834; for 491 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 313 | 491 | 74 | 1.37 | $135,829 | $39,834 |
| 2023 | 299 | 463 | 73 | 1.33 | $124,738 | $39,663 |
| 2022 | 119 | 168 | 71 | 1.66 | $43,978 | $14,261 |
| 2021 | 30 | 37 | 71 | 3.23 | $8,473 | $2,153 |
| 2020 | 41 | 67 | 70 | 3.65 | $17,367 | $3,747 |
| 2019 | 70 | 94 | 71 | 2.34 | $11,066 | $2,342 |
| 2018 | 328 | 416 | 71 | 1.39 | $45,000 | $19,663 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 202 | $22,037 | $80 |
| New patient visit (45+ min) | 157 | $15,792 | $101 |
| Short return visit (20+ min) | 25 | $1,428 | $57 |
2022: 2 services
| New patient visit (45+ min) | 55 | $5,904 | $107 |
| Return visit (30+ min) | 54 | $5,029 | $85 |
2021: 1 service
| Short return visit (20+ min) | 13 | $688 | $46 |
2020: 1 service
| Return visit (30+ min) | 14 | $1,230 | $53 |
2019: 2 services
| Short return visit (20+ min) | 45 | $1,060 | $24 |
| Return visit (30+ min) | 28 | $939 | $32 |
2018: 3 services
| Short return visit (20+ min) | 226 | $11,225 | $46 |
| Return visit (30+ min) | 69 | $4,957 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,101 | $48 |
Medicaid work
$498 in 2019
Medicaid paid $498 for 37 billed services this clinician did in 2019, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 37 | $498 |
| 2019 | 37 | 1 | 17 | $498 |
| 2018 | 31 | 1 | 14 | $425 |
See the largest Medicaid services in earlier years
2018
| Short return visit (20+ min) | 31 | $425 |
Drugs they prescribed that Part D paid
$141,697
Pharmacies billed $141,697 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 553) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
316 generic and 237 brand-name prescriptions · $141,697 in drug cost · 36 antibiotic prescriptions to 33 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 106 | $75,729 | $714 |
| Breo Ellipta | 16 | $9,524 | $595 |
| Fluticasone-Salmeterol | 32 | $3,110 | $97 |
| Albuterol Sulfate Hfa | 73 | $1,786 | $24 |
| Budesonide-Formoterol | 11 | $1,532 | $139 |
See all 12 drugs
| Trelegy Ellipta | 106 | $75,729 | $714 |
| Breo Ellipta | 16 | $9,524 | $595 |
| Fluticasone-Salmeterol | 32 | $3,110 | $97 |
| Albuterol Sulfate Hfa | 73 | $1,786 | $24 |
| Budesonide-Formoterol | 11 | $1,532 | $139 |
| Azelastine | 34 | $717 | $21 |
| Ipratropium | 39 | $712 | $18 |
| Fluticasone Propionate | 48 | $418 | $9 |
| Prednisone | 54 | $134 | $2 |
| Montelukast | 24 | $84 | $3 |
| Omeprazole | 15 | $72 | $5 |
| Azithromycin | 14 | $57 | $4 |
Year by year
| 2024 | 553 | 187 | 0% (0) | 43% | $141,697 |
| 2023 | 346 | 133 | 0% (0) | 42% | $60,691 |
| 2022 | 79 | 39 | None | None | $10,301 |
| 2021 | 111 | 45 | None | None | $10,116 |
| 2020 | 254 | 82 | None | None | $100,841 |
| 2019 | 855 | 283 | 0% (0) | 40% | $177,494 |
| 2018 | 483 | 227 | None | 30% | $49,348 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Trelegy Ellipta | 30 | $23,039 | $768 |
| Symbicort | 20 | $7,064 | $353 |
| Albuterol Sulfate Hfa | 54 | $1,719 | $32 |
| Fluticasone Propionate | 50 | $508 | $10 |
| Azelastine | 17 | $490 | $29 |
| Ipratropium | 13 | $363 | $28 |
| Omeprazole | 13 | $202 | $16 |
| Prednisone | 33 | $115 | $3 |
| Montelukast | 14 | $85 | $6 |
2021: 1 drug
| Potassium Chloride | 11 | $256 | $23 |
2020: 6 drugs
| Symbicort | 29 | $9,575 | $330 |
| Stiolto Respimat | 12 | $5,361 | $447 |
| Incruse Ellipta | 13 | $4,750 | $365 |
| Montelukast | 21 | $296 | $14 |
| Fluticasone Propionate | 12 | $190 | $16 |
| Acyclovir | 13 | $144 | $11 |
2019: 21 drugs
| Trelegy Ellipta | 28 | $20,109 | $718 |
| Symbicort | 46 | $19,194 | $417 |
| Spiriva Respimat | 30 | $16,256 | $542 |
| Breo Ellipta | 27 | $10,071 | $373 |
| Incruse Ellipta | 26 | $9,668 | $372 |
| Bevespi Aerosphere | 12 | $6,602 | $550 |
| Stiolto Respimat | 15 | $6,116 | $408 |
| Anoro Ellipta | 12 | $5,000 | $417 |
| Arnuity Ellipta | 19 | $4,682 | $246 |
| Proair Hfa | 14 | $1,822 | $130 |
| Ventolin Hfa | 24 | $1,506 | $63 |
| Azelastine | 30 | $1,488 | $50 |
| Doxycycline Hyclate | 57 | $1,263 | $22 |
| Fluticasone Propionate | 51 | $943 | $18 |
| Armodafinil | 12 | $704 | $59 |
| Prednisone | 145 | $640 | $4 |
| Montelukast | 42 | $554 | $13 |
| Azithromycin | 43 | $515 | $12 |
| Ropinirole | 16 | $245 | $15 |
| Clonazepam | 32 | $245 | $8 |
| Levofloxacin | 11 | $109 | $10 |
2018: 12 drugs
| Symbicort | 30 | $11,621 | $387 |
| Spiriva Respimat | 25 | $10,253 | $410 |
| Ventolin Hfa | 21 | $1,361 | $65 |
| Proair Hfa | 13 | $1,125 | $87 |
| Azelastine | 14 | $670 | $48 |
| Prednisone | 128 | $641 | $5 |
| Doxycycline Hyclate | 30 | $613 | $20 |
| Ropinirole | 12 | $320 | $27 |
| Azithromycin | 26 | $274 | $11 |
| Montelukast | 24 | $266 | $11 |
| Fluticasone Propionate | 21 | $259 | $12 |
| Amoxicillin-Clavulanate Potass | 17 | $162 | $10 |
Money from drug and device companies
$348 in 2025
| 2025 | 4 | 4 | None | $348 |
| 2024 | 6 | 12 | None | $524 |
| 2023 | 6 | 8 | None | $249 |
| 2022 | 1 | 1 | None | $28 |
| 2021 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Reblozyl | $126 | 1 payment
|
| Genmab U.S. | Epkinly | $125 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $86 | 1 payment
|
| Breas Medical | Vivo 45 Ls | $11 | 1 payment
|
See all 4 published payments
| Breas Medical | Meals · 2025-07-23 | Vivo 45 Ls | $11 |
| Genmab U.S. | Meals · 2025-05-29 | Epkinly | $125 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-30 | None | $86 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-12 | Reblozyl | $126 |
See earlier years (2024, 2023, 2022, 2021)
2024: $524
| Regeneron Healthcare Solutions | Dupixent | $386 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $57 | 3 payments
|
| Harmony Biosciences | Wakix | $24 | 1 payment
|
| Resmed | Airsense | $21 | 1 payment
|
| Grifols USA | Prolastin-C Liquid | $20 | 1 payment
|
| Avadel CNS Pharmaceuticals | Lumryz | $17 | 1 payment
|
2023: $249
| GlaxoSmithKline | Trelegy Ellipta | $144 | 3 payments
|
| Inspire Medical Systems | Inspire | $28 | 1 payment
|
| Harmony Biosciences | Wakix | $25 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Breztri | $17 | 1 payment
|
| Resmed | Airsense | $17 | 1 payment
|
2022: $28
| Amgen | Tezspire | $28 | 1 payment
|
2021: $12
| AstraZeneca Pharmaceuticals LP | Breztri | $12 | 1 payment
|
Professional record
- NPI
- 1710492145
- Licence
- NC 0010-07722
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2102 Harrisburg Pike, Lancaster, PA, 17601
- NPI first listed
- 2017-12-07
- NPI last updated
- 2026-09-15
- NPI record certified
- 2026-09-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 509 Biltmore Ave, Asheville, NC, 28801 · 5 Vanderbilt Park Dr, Asheville, NC, 28803